What is "peptide therapy," and why does the safety question get complicated?
A peptide is a short chain of amino acids — the same building blocks that make up proteins. Your body already makes hundreds of them, and they act as signals: telling the stomach to empty, the pancreas to release insulin, fat cells to release energy. Peptide therapy, in the broadest sense, means using a peptide compound as a treatment.
The complicated part is that "peptide therapy" covers an enormous range of things. At one end you have medicines like semaglutide (sold as Ozempic and Wegovy) that have been studied in tens of thousands of people and approved by the FDA. At the other end you have compounds like BPC-157 that have never completed a human clinical trial. Lumping them all under the same label is a bit like asking "is surgery safe?" — it depends entirely on what kind.
The single most important thing to know before asking about safety is this: what regulatory status does the specific compound have? That one question splits the world of peptide therapy into two very different categories, and the safety evidence in each category is completely different.
Which peptides are FDA-approved — and what does that mean for safety?
FDA approval is not a rubber stamp. It means a drug company ran multiple phases of clinical trials, involving hundreds to thousands of people, and submitted the complete safety and efficacy data to the FDA for independent review. The FDA then decided the benefit outweighs the risk for a specific use. That process usually takes a decade and costs billions of dollars. It is the reason approved medicines have a known safety profile — because someone studied them carefully in people.
In the peptide world, several compounds have cleared this bar. Semaglutide (GLP-1 receptor agonist, sold as Ozempic for type 2 diabetes and Wegovy for weight management) and tirzepatide (dual GIP and GLP-1 receptor agonist, sold as Mounjaro and Zepbound) are FDA-approved. Tesamorelin (sold as Egrifta) is FDA-approved for excess abdominal fat in people with HIV-associated lipodystrophy. GLP-2 analogues, insulin analogues, and several other peptide-based drugs round out the approved list.
For these approved compounds, safety is not a mystery. The clinical trials are published, the side-effect rates are known, and the FDA prescribing information documents who should not use them and why. That is what "established safety record" actually means.
| Compound (brand name) | FDA status | Approved for | Safety record |
|---|---|---|---|
| Semaglutide (Ozempic, Wegovy) | FDA-approved | Type 2 diabetes; weight management | Established — large RCTs (STEP 1, SELECT); long-term CV data available |
| Tirzepatide (Mounjaro, Zepbound) | FDA-approved | Type 2 diabetes; weight management | Established — large RCT (SURMOUNT-1); FDA-approved Nov 2023 |
| Tesamorelin (Egrifta WR) | FDA-approved | Excess abdominal fat in HIV lipodystrophy | Established — two 26-week RCTs; generally well tolerated; serious AEs <4% |
| BPC-157 | NOT FDA-approved | None — investigational | Human data "extremely limited"; only three small pilot studies; no completed RCT |
| CJC-1295, Ipamorelin, Sermorelin, etc. | NOT FDA-approved (except as compounded drugs under specific conditions) | None — off-label or investigational | No published large-scale human safety trials |
What side effects do FDA-approved GLP-1 medicines cause?
Because they have been studied in large trials, the side effects of semaglutide and tirzepatide are well documented. The most common ones are digestive: nausea, vomiting, diarrhea, and constipation. These happen because the medicine slows down how quickly your stomach empties — a feature, not a flaw — and your gut takes time to adjust.
In the STEP 1 trial of semaglutide, most of these digestive symptoms were rated mild to moderate and were most common during the early weeks when the dose was being increased. They tended to ease as the body adjusted. The tirzepatide data from the SURMOUNT-1 trial showed a similar pattern. The standard way doctors manage this is by starting at a low dose and increasing gradually over weeks or months.
Rare but more serious events exist too. Pancreatitis (inflammation of the pancreas), gallbladder problems, and — based on animal studies — a potential signal for a rare type of thyroid tumor are listed on the FDA prescribing labels. Because these are rare, trials showed them at low rates, but they are reasons why anyone starting these medicines talks through their history with a doctor first. These medicines are also not right for everyone; people with certain personal or family histories may be advised against them.
The SELECT trial tracked over 17,000 people with cardiovascular disease and excess weight taking semaglutide or a placebo for several years. It found that semaglutide reduced serious heart events — things like heart attacks and strokes — by about 20 percent compared with the placebo group. That is a long-term cardiovascular safety and efficacy signal from real-world-sized trial numbers. It does not erase the short-term digestive side effects, but it adds important context: for the right patient, the benefit picture is quite good.
What about tesamorelin?
Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue. It is a peptide that stimulates the pituitary gland to make more growth hormone, which in turn reduces the excess visceral fat that builds up in some people treated for HIV. It is the only FDA-approved compound in its class.
A 2011 review of the two pivotal 26-week trials found tesamorelin was generally well tolerated. Serious adverse events occurred in fewer than 4% of participants. The most common side effects were those typical of mildly elevated growth hormone: joint aches, headaches, and mild fluid retention, particularly in the early weeks. The prescribing information notes it is not approved for weight management in people without HIV, and it carries a contraindication for people with active malignancy or certain other conditions.
The key point for the safety question is that tesamorelin has a known profile because it was studied in people, reviewed by the FDA, and approved with clear labelling. Whether that profile applies to someone using it for a different purpose, off-label, is a separate question — and one that your doctor needs to weigh in on.
What about investigational peptides — the ones that are NOT FDA-approved?
This is where the safety question gets genuinely hard to answer. Compounds like BPC-157, CJC-1295, ipamorelin, epithalon, MOTS-c, and dozens of others are widely discussed in fitness and biohacking communities. They are not FDA-approved drugs. They are investigational — which means the safety evidence in humans is thin or entirely absent.
Take BPC-157 as an example. It has been studied extensively in preclinical (animal and cell) models, where it shows interesting effects on healing and inflammation. But a 2025 systematic narrative review of BPC-157 in humans found that human evidence was "extremely limited" — only three small pilot studies had been published, and none were completed randomised controlled trials. That means for humans, the safety record is essentially a blank page. The preclinical data are encouraging to researchers, but encouraging animal data does not automatically translate to safety in people.
The situation is similar for most unapproved peptides. They are sold under labels like "for research use only" precisely because they have not gone through the approval process. Using them outside of a clinical trial means using a compound whose human safety profile — what doses are toxic, how it interacts with other medicines, who is at risk for serious reactions — has simply not been established.
None of this means these compounds are definitely dangerous. It means the honest answer is: we do not know, because the research has not been done in people at scale. The absence of safety data is not the same as a green light. It is an unknown, which is a different thing.
Why does it matter if a medicine is "investigational"?
When a compound is described as investigational, it means it is still in the research phase — it has not completed the clinical trial process that would tell us whether it is safe and effective in humans. The gap between "looks promising in the lab" and "proven safe in people" is enormous, and many compounds that showed promise in early research did not make it through human trials.
FDA approval requires a company to show not just that a drug works, but that the benefit is real, the risks are understood, who it is appropriate for and who it is not, and how to use it safely. Investigational compounds have none of that documentation completed. When someone uses one outside a clinical trial, they are essentially operating without the safety net that the approval process is designed to provide.
This does not mean all investigational peptides will turn out to be harmful. It means the risk is unknown and unquantified. For some people, that is an acceptable trade-off; for others, it is not. The person best placed to help weigh that trade-off is a licensed clinician who knows your full health picture.
What does clinician monitoring look like — and why does it help?
Even for FDA-approved peptides, safe use is not just about the compound itself — it is about monitoring. A licensed clinician who prescribes semaglutide or tirzepatide will typically check in on weight, blood pressure, blood glucose, kidney function, and other relevant markers over time. Those check-ins exist because individual responses vary and because rare side effects need to be caught early.
For investigational compounds, monitoring becomes even more important, precisely because the safety profile is unknown. If a clinician is supervising use of an unapproved peptide, they should at minimum be tracking liver enzymes, kidney function, relevant hormones, and anything the compound is theoretically expected to affect. The idea is that if something goes wrong, it is caught before it becomes serious.
The practical challenge is keeping track of all of it: which compound you are taking, at what dose, when you last had bloodwork done, and what the results showed. The more complex a protocol gets, the harder it is to hold that picture in your head — or even in a collection of spreadsheets and text messages.
Keeping track with PeptidePanel
If a licensed clinician has set you up on a peptide protocol — whether that is an FDA-approved GLP-1 medicine or a supervised investigational compound — there is real day-to-day information to keep straight: dosing schedule, next injection, upcoming labs, and how your results are trending over time.
PeptidePanel is a tracking tool built for exactly that. It organises the protocol your clinician set, charts your biomarker results, and sends reminders when something is due. It does not sell, source, or recommend any compound — it is the notebook that keeps your doctor's plan organised and visible, so you and your clinician can see the full picture at a glance.